

Europe COVID-19 tracker

Battling on multiple fronts

- The COVID-19 winter wave in Europe is still intensifying and the Omicron variant introduces further downside risks
- European countries have responded by adopting more stringent restrictions and measures to boost vaccine uptake
- The ECB is facing a difficult situation due to surging inflation and the Omicron variant represents an additional headache

The Omicron variant adds uncertainty to an already challenging situation

The emergence of the COVID-19 Omicron variant is posing downside risks to the global economy, given its potential for increased vaccine evasion compared to previous variants. These risks could be particularly acute in Europe, which is already facing a severe COVID-19 wave led by the Delta variant. The European Centre for Disease Prevention and Control (ECDC) indicated on 30 November that 44 confirmed cases of Omicron have been reported by 11 EU/EEA countries, with all cases being asymptomatic or with mild symptoms. However, uncertainty regarding the features of this new variant is still high, and so a downside scenario of renewed strict lockdown measures due to Omicron cannot be ruled out at this stage.

Multipronged response from the European governments

Given this higher uncertainty, several European countries have restricted travel from southern Africa. Some countries went further, like the UK where all travellers are now required to have a PCR test by day two of arrival and have to self-isolate until they receive a negative result. Beyond travel restrictions, several governments have also adopted new measures to support vaccination uptake, via looser eligibility for booster shots (like in the UK or in France, where the booster will be required to keep health passes valid) or more stringent measures (fines in Greece for unvaccinated people over 60). Finally, due to the deteriorating situation linked to the current wave, domestic restrictions have been tightened further in some countries, including in the Netherlands where bars, restaurants and shops have been ordered to close by 5pm for the next three weeks. Germany, where pressure on hospitals is rising (Chart 4), could also announce new measures on Thursday, both in terms of restrictions and vaccinations (Bloomberg, 30 November).

A more challenging backdrop for the ECB

The Omicron variant is an additional headache for the ECB, which is already facing a complex backdrop given the current surge in inflation (Charts 21-22). Increased and prolonged travel restrictions could provide a further blow to countries dependent on tourism, such as Spain. In a pessimistic scenario of renewed lockdowns, both demand and supply could be significantly impacted, resulting in higher uncertainty around the inflation outlook.

This is a Free-to-View version of a report by the same title published on 01-Dec-21. Please contact your HSBC representative or email <u>AskResearch@hsbc.com</u> for more information.

Disclosures & Disclaimer

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, which forms part of it.

Free to View Economics - Europe

Chantana Sam Economist HSBC Continental Europe

Issuer of report: HSBC Continental Europe

View HSBC Global Research at: https://www.research.hsbc.com





Still no signs of a peak in the winter wave

1. Case numbers in the Big 4 plus UK have topped their previous peak levels







Source: Refinitiv Datastream, HSBC. Note: Weekend numbers are reported as 0 so "7-days to" does not include Saturday and Sunday.

3. ... and in France



4. In Germany, pressure on hospitals is becoming particularly intense



We acknowledge the assistance of Yash Dewan, HSBC Bank plc, in the preparation of this report.





Renewed momentum in vaccination

5. The pace of vaccination has picked up in some countries, especially Germany



6. The UK is still leading the way on booster shots



7. A large portion of elderly people has still not received a booster shot in France...



8. ... and Germany's rollout is even more



9. There is still a significant divide in vaccination coverage between eastern and western Europe



Source: Our World in Data, HSBC.



New restrictions are focused on unvaccinated people

10. Latest on the restrictions from the major European countries

Country	Latest lockdown measures
Germany	On 19 November, a new Infection Protection Act was approved by the Bundesrat, after having passed the Bundestag one day before. With the amendment, uniform nationwide coronavirus protection measures are possible even after the determination or the epidemic situation of national scope expires on 25 November. A number of new measures were introduced, eg, the 3G regulation (vaccinated, recovered, tested) will apply in the workplace and in public transport. Protective measures such as mandatory mask-wearing and distance regulations can be continued. Employees are encouraged to work from home.
	Following the surge in infection and incidence numbers to all-time highs and an accompanying rise in hospitalisation numbers, acting Chancellor Merkel and the Heads of the Federal states announced a three-step concept on 18 November based on the development of the hospitalisation rate. If there are more than three hospitalisations per 100k inhabitants in a federal state, a 2G rule will apply; if the hospitalisations rate rises above six, the 2G+ rule will apply in the federal state (which means vaccinated and recovered persons must present an additional rapid antigen test). If the hospitalisation rate crosses the threshold of nine, contact restrictions will apply. However, the ordering of curfews and accommodation bans or the area-wide closure of shops, schools, restaurants or sports facilities are excluded. The regulations are to apply nationwide until 19 March 2022, but can be extended by three months.
France	In metropolitan France, current restrictions are focused on unvaccinated people (aged above 12) via the imposition of a COVID-19 health pass (i.e. a proof of vaccination or a negative test) to access some activities (museums, cinemas, bars, restaurants, large shopping malls, hospitals and some long-distance transport such as airplanes and trains). In addition, vaccination is mandatory for some key occupations (healthcare, firemen) and breaches can lead to penalties.
	On 9 November, President Macron announced that for people eligible to receive booster shots (i.e. people aged above 65 and people with higher risk of developing serious illness), such a booster shot will be required from mid-December to have a valid COVID-19 pass. On 25 November, the government announced that all adults will be eligible for booster shots from December (5 months after the latest dose) and that this booster will be required 7 months after the latest dose to not lose the health pass.
	The Omicron variant has also led the government to adopt travel restrictions from southern Africa. In addition, all non- EU travellers coming to France will have to present a negative PCR test, even if they are vaccinated.
Spain	On 9 May, the state of emergency expired and was not extended by the government. With that, the nationwide curfew also came to an end. Some restrictions remain in place in some areas with some limitations to the opening hours of bars, restaurants and clubs (2am or 4am if all the staff is vaccinated or had a negative COVID-19 test), to the maximum number of people allowed for gatherings (8 or 12, depending on the region) and the capacity utilisation of buildings for events. The freedom to travel across regions has been re-established with no regions maintaining the external border closures in place. From 6 June, masks are no longer necessary in outdoor settings where social distancing is observed.
	Some regions have introduced a 'green pass' requirement for entering cultural and sports events, and some are also considering this for restaurants and bars. Spain's external frontier remains open. More regions are now implementing localised nightly curfews for people without a 'green pass'. For entry into the country, a proof of vaccination or a negative COVID-19 test within 48 hours of entry is required.
Italy	Currently, all the Italian territory is in the 'white' category with hardly any restrictions (other than obligatory mask wearing indoors – since 28 June, masks are no longer required outdoors – and some social distancing requirements). About twenty municipalities in the Northern region of Alto Adige (which has more independence to set its own rules) are now back in the 'red zone' with curfews form 8pm to 5am and several activities being shut. But so far nothing has been agreed at the national level in terms of moving from the 'white zone' even to the 'yellow zone'.
	The government has introduced a 'green pass' requirement (full vaccination or negative COVID-19 test) to go into restaurants and bars (indoors), theatres, cinemas public transport, as well as some outdoors venues, and attend concerts and sporting events. The government has recently announced that from 15 October until the end of the year the 'green pass' will be required for all public and private sector workers, with high penalties for the non-compliant. The government has announced the introduction of a "super green pass" from 6 December, restricting access to social events (cinemas, restaurants, theatres, etc) for people that are unvaccinated or have had the virus in the past six months – so it's no longer enough to have had a negative test (<i>Corriere della Sera</i> , 24 November). A negative test would still be fine to go to work, though. Children aged 5-11 years can also be vaccinated from Monday 29 November As for international travel, people arriving from the EU no longer have to quarantine, but they will be required to show a negative COVID-19 test undertaken within 48 hours before departure (unless fully vaccinated).
UK	Having been in lockdown through the first quarter of the year, the UK economy has now largely re-opened, so there are essentially no restrictions on social contact or economic activity. For Scotland, Wales and Northern Ireland, mask wearing has remained mandatory in public places throughout the reopening, and England reintroduced this on 30 November following the emergence of the Omicron variant. Scotland and Wales have 'vaccine passport' systems in place for nightclubs and some other venues. The Scottish government is considering extending the vaccine passport system to additional venues like cinemas and theatres.
	New travel rules were announced on 17 September, which divides arrivals into two groups – 'red list' and the rest of the world. Under the new system, entry into the UK from the red list remains banned to non-UK or Irish nationals. For those who cannot be refused entry from these countries – i.e. returning British or Irish nationals – a mandatory 10-day quarantine in government- approved accommodation applies. On 1 November, all remaining countries were removed from this list, but ten have now been added back, following the emergence of the Omicron variant (all in southern Africa). For those who are fully vaccinated, arriving into England, Scotland, Wales or Northern Ireland from the rest of the world, pre-departure tests are no longer necessary, but a PCR test is now required by Day Two, with passengers required to self-isolate until they receive a negative result. For those who are not fully vaccinated, PCR tests are required before and after arrival.
	The new regulations which came into effect on 30 November (mandatory masks in England and PCR tests and self-isolation for arrivals) will be reviewed in three weeks, around 18-21 December.

Source: Country data, HSBC



Limited impact of the latest restrictions on mobility so far

11. Restrictions have become slightly more stringent in the UK...



12. ...and in the eurozone



Source: Google mobility, Oxford COVID-19 Government response Tracker, HSBC Note:* 7-day moving average

Source: Google mobility, Oxford COVID-19 Government response Tracker, HSBC Note: *7-day moving average

13. Retail mobility has generally edged down but it is not plunging...



14. ...and it's also true for workplace activity





Fears over the Omicron variant should impact travel activity

15. The Omicron variant has spread quickly in some parts of Africa...



16. ...while its presence in Europe seems to be low for the time being





Source: GISAID, HSBC. Note: Geographic regions only contain countries that submit genome sequencing data on Omicron which are currently few. Eg. Africa refers to only a few countries, including South Africa. *Europe doesn't include UK

17. However, it has already been detected in sequencing data for some countries



Source: GISAID, HSBC.

19. Travel restrictions are likely to weigh further on flight activity...



20. ...which was already softer in November, possibly due to the COVID-19 situation



% Omicron: Relative variant genome frequency per region %



18. Delta is still the dominant variant in Europe





Surging inflation remains a source of concern

21. Big upside surprise for eurozone inflation in November



22. Higher price pressures are also evident in the services sector



Source: Refinitiv Datastream, HSBC



23. Renewed upward pressures on energy prices in the UK



Source: Refinitiv Datastream, HSBC.

25. Eurozone consumers are still expecting higher inflation in the future...



24. Still no signs of second round effects via wages in the eurozone



26. ...but sentiment on the labour market remains relatively upbeat





COVID-19 in Western Europe

27. German infection numbers are still rising rapidly



28. In France, the COVID-19 situation is clearly worsening



Source: Refinitiv Datastream, HSBC.

29. Italy is starting to see more of an increase in infection numbers...



Source: Refinitiv Datastream, HSBC.

31. In the UK, case numbers are more stable, but at a high level



Source: Refinitiv Datastream, HSBC.

30. Similarly, Spain is seeing rising cases, even though the level remains relatively low



Source: Refinitiv Datastream, HSBC.

32. Cases have risen sharply in Switzerland



Source: Refinitiv Datastream, HSBC.







35. Conversely, Sweden is still not significantly impacted by the current wave



Source: Refinitiv Datastream, HSBC.





34. Norway's cases are now up more significantly



36. Irish case numbers are now increasing very rapidly



Source: Refinitiv Datastream, HSBC.

38. ...while they remain close to an all-time high in Greece



Source: Refinitiv Datastream, HSBC.

Source: Refinitiv Datastream, HSBC.



Fiscal measures (in the Big 4 eurozone countries and the UK)

39. Fiscal policy was highly supportive of growth last year even if a significant chunk of support did not make it into the economy due to restrictions and was actually saved



Source: The Calculations based on national statuca institutes, curvesta and caropean commission, 2020 budgets and anentiments. Notes: "Discounting the impact (0.9% of GDP) of the incorporation of "Sareb' under the public sector. The "Economic Cycle' component for eurozone countries and the Big 4 includes the 'normal' short-time work compensation schemes but not the extensions and more generous terms agreed in response to the COVID-19 crisis...





Source: HSBC calculations based on 2022 Draft Budget Plans, Eurostat and European Commission, 2020 budgets and amendments. Notes: The 'Economic Cycle' component for eurozone countries and the Big 4 includes the 'normal' short-time work compensation schemes but not the extensions and more generous terms agreed in response to the COVID-19 crisis.



41. In 2022, the domestic fiscal policy stance should remain mildly expansionary, and even more so including the additional support provided by the Next Generation EU (NGEU) fund

Source: HSBC calculations based on 2022 Draft Budget Plans, Eurostat and European Commission, 2020 budgets and amendments. Notes: The adjusted series takes into account that due to ongoing restrictions at least part of the stimulus implemented last year and this year did not actually feed through into the economy but will only do so once restrictions are lifted.



Disclosure appendix

Analyst Certification

The following analyst(s), economist(s), or strategist(s) who is(are) primarily responsible for this report, including any analyst(s) whose name(s) appear(s) as author of an individual section or sections of the report and any analyst(s) named as the covering analyst(s) of a subsidiary company in a sum-of-the-parts valuation certifies(y) that the opinion(s) on the subject security(ies) or issuer(s), any views or forecasts expressed in the section(s) of which such individual(s) is(are) named as author(s), and any other views or forecasts expressed herein, including any views expressed on the back page of the research report, accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Chantana Sam.

Important disclosures

This document has been prepared and is being distributed by the Research Department of HSBC and is not for publication to other persons, whether through the press or by other means.

This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy the securities or other investment products mentioned in it and/or to participate in any trading strategy. Advice in this document is general and should not be construed as personal advice, given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. If necessary, seek professional investment and tax advice.

Certain investment products mentioned in this document may not be eligible for sale in some states or countries, and they may not be suitable for all types of investors. Investors should consult with their HSBC representative regarding the suitability of the investment products mentioned in this document and take into account their specific investment objectives, financial situation or particular needs before making a commitment to purchase investment products.

The value of and the income produced by the investment products mentioned in this document may fluctuate, so that an investor may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Value and income from investment products may be adversely affected by exchange rates, interest rates, or other factors. Past performance of a particular investment product is not indicative of future results.

HSBC and its affiliates will from time to time sell to and buy from customers the securities/instruments, both equity and debt (including derivatives) of companies covered in HSBC Research on a principal or agency basis or act as a market maker or liquidity provider in the securities/instruments mentioned in this report.

Analysts, economists, and strategists are paid in part by reference to the profitability of HSBC which includes investment banking, sales & trading, and principal trading revenues.

Whether, or in what time frame, an update of this analysis will be published is not determined in advance.

For disclosures in respect of any company mentioned in this report, please see the most recently published report on that company available at www.hsbcnet.com/research. HSBC Private Banking clients should contact their Relationship Manager for queries regarding other research reports. In order to find out more about the proprietary models used to produce this report, please contact the authoring analyst.

Additional disclosures

- 1 This report is dated as at 01 December 2021.
- 2 All market data included in this report are dated as at close 01 December 2021, unless a different date and/or a specific time of day is indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Information Barrier procedures are in place between the Investment Banking, Principal Trading, and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.
- 4 You are not permitted to use, for reference, any data in this document for the purpose of (i) determining the interest payable, or other sums due, under loan agreements or under other financial contracts or instruments, (ii) determining the price at which a financial instrument may be bought or sold or traded or redeemed, or the value of a financial instrument, and/or (iii) measuring the performance of a financial instrument or of an investment fund.



Disclaimer

Legal entities as at 1 December 2020

'UAE' HSBC Bank Middle East Limited, DIFC; HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Taiwan) Corporation Limited; 'CA' HSBC Securities (Canada) Inc.; 'France' HSBC Continental Europe; 'Spain' HSBC Continental Europe, Sucursal en España; 'Italy' HSBC Continental Europe, Italy; 'Sweden' HSBC Continental Europe Bank, Sweden Filial ; 'DE' HSBC Trinkaus & Burkhardt AG, Düsseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt SAE, Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Securities Branch; The Hongkong and Shanghai Banking Corporation Limited, Seoul Branch; HSBC Securities (South Africa) (Pty) Ltd, Johannesburg; HSBC Bank plc, London, Tel Aviv; 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler AS, Istanbul; HSBC México, SA, Institución de Banca Múltiple, Grupo Financiero HSBC; HSBC Bank Australia Limited; HSBC Bank Argentina SA; HSBC Saudi Arabia Limited; The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR; The Hongkong and Shanghai Banking Corporation Limited, Real Branch; PT Bank HSBC Indonesia; HSBC Diahai Securities Limited; Banco HSBC S.A.

Issuer of report HSBC Continental Europe 38 avenue Kléber 75116 Paris, France Telephone: +33 1 40 70 70 40 Fax: +33 1 40 70 70 09 Website: www.research.hsbc.com

This document has been issued by HSBC Continental Europe ("HSBC") for the information of its customers only.

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Department of HSBC only and are subject to change without notice. From time to time research analysts conduct site visits of covered issuers. HSBC policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be accounted for in the supervisory board or any other committee of those companies. The information and opinions contained within the research reports are based upon rates of taxation applicable at the time of publication but which are subject to change from time to income may go down as well as up and you may not get back the full amount invested. Where an investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed. (AMF) and the ACPR, controlled by the European Central Bank.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. The information contained herein is under no circumstances to be construed as investment advice and is not tailored to the needs of the recipient. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK, this publication is distributed by HSBC Bank plc for the information of its Clients (as defined in the Rules of FCA) and those of its affiliates only. Nothing herein excludes or restricts any duty or liability to a customer which HSBC Bank plc has under the Financial Services and Markets Act 2000 or under the Rules of FCA and PRA. A recipient who chooses to deal with any person who is not a representative of HSBC Bank plc in the UK will not enjoy the protections afforded by the UK regulatory regime. HSBC Bank plc is regulated by the Financial Conduct Authority and the Prudential Regulation Authority. If this research is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate.

In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. Only Economics or Currencies reports are intended for distribution to a person who is not an Accredited Investor, Expert Investor or Institutional Investor as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors as defined in SFA. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch accepts legal responsibility for the contents of reports pursuant to Regulation 32C(1)(d) of the Financial Advisers Regulations. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch is regulated by the Monetary Authority of Singapore. Recipients in Singapore should contact a "Hongkong and Shanghai Banking Corporation Limited, Singapore Branch" representative in respect of any matters arising from, or in connection with this report. Please refer to The Hongkong and Shanghai Banking Corporation Limited Singapore Branch's website at www.business.hsbc.com.sg for contact details.

In the European Economic Area, this publication has been distributed by HSBC Continental Europe or by such other HSBC affiliate from which the recipient receives relevant services.

In Australia, this publication has been distributed by The Hongkong and Shanghai Banking Corporation Limited (ABN 65 117 925 970, AFSL 301737) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). Where distributed to retail customers, this research is distributed by HSBC Bank Australia Limited (ABN 48 006 434 162, AFSL No. 232595). These respective entities make no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient.

This publication is distributed in New Zealand by The Hongkong and Shanghai Banking Corporation Limited, New Zealand Branch incorporated in Hong Kong SAR.

In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. In Hong Kong, this document has been distributed by The Hongkong and Shanghai Banking Corporation Limited in the conduct of its Hong Kong regulated business for the information of its institutional and professional customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited makes no representations that the products or services mentioned in this document are available to persons in Hong Kong or are necessarily suitable for any particular person or appropriate in accordance with local law. All inquiries by such recipients must be directed to The Hongkong and Shanghai Banking Corporation Limited. It may not be further distributed in whole or in part for any purpose. In Korea, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Secul Securities Branch ("HBAP SLS") for the general information of professional investors specified in Article 9 of the Financial Investment Services and Capital Markets Act ("FSCMA"). This publication is not a prospectus as defined in the FSCMA. It may not be further distributed in in whole or in part for any purpose. HBAP SLS is regulated by the Financial Services Commission and the Financial Supervisory Service of Korea.

In Canada, this document has been distributed by HSBC Securities (Canada) Inc. (member IIROC), and/or its affiliates. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offense. In Brazil, this document has been distributed by Banco HSBC S.A. ("HSBC Brazil"), and/or its affiliates. As required by Instruction No. 598/18 of the Securities and Exchange Commission of Brazil (Comissão de Valores Mobiliários), potential conflicts of interest concerning (i) HSBC Brazil and/or its affiliates; and (ii) the analyst(s) responsible for authoring this report are stated on the chart above labelled "HSBC & Analyst Disclosures".

If you are an HSBC Private Banking ("PB") customer with approval for receipt of relevant research publications by an applicable HSBC legal entity, you are eligible to receive this publication. To be eligible to receive such publications, you must have agreed to the applicable HSBC entity's terms and conditions for accessing research and the terms and conditions of any other internet banking service offered by that HSBC entity through which you will access research publications ("the Terms"). Distribution of this publication is the sole responsibility of the HSBC entity with whom you have agreed the Terms. If you do not meet the aforementioned eligibility requirements please disregard this publication and, if you are a customer of PB, please notify your Relationship Manager. Receipt of research publications is strictly subject to the Terms and any other conditions or disclaimers applicable to the provision of the publications that may be advised by PB.

© Copyright 2021, HSBC Continental Europe, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Continental Europe. MCI (P) 028/02/2021, MCI (P) 017/10/2021